Despite standard therapy, cytomegalovirus (CMV) disease recurs in a significant proportion
of organ transplant recipients. The kinetics of CMV load in response to therapy may allow …

Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in
24 solid organ transplant patients with CMV infection or disease who received a fixed 14 …

CMV disease often recurs after initially successful antiviral therapy. We retrospectively
determined in a group of 36 organ transplant patients whether clinical, virological, or …

Background Cytomegalovirus (CMV) continues to be a major problem post-transplantation;
early markers for predicting patients at risk of CMV disease are needed. Peak CMV load in …

The availability of valganciclovir (VGCV) has significantly simplified the treatment of human
cytomegalovirus (HCMV) infection after solid-organ transplantation. We show that there was …

Background Although initial therapy for cytomegalovirus (CMV) is usually successful, a
significant subset of patients may have recurrent viremia. However, the epidemiology and …

The degree and dynamics of cytomegalovirus (CMV) replication were investigated in blood
samples that were prospectively collected in the context of a placebo-controlled study …

Background: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease
in organ transplant recipients is successful in> 90% of individuals, relapsing disease …

Despite prophylaxis, cytomegalovirus (CMV) disease is common in donor seropositive
(D+)/recipient seronegative (R-) transplant patients after cessation of prophylaxis. Early …

Predictors of recurrent cytomegalovirus (CMV) disease after the first episode of successfully
treated CMV disease in orthotopic liver transplant recipients were studied. Recurrent CMV …